

## **Dicot Pharma to present at the Oppenheimer 36th Healthcare Life Sciences Conference**

**Uppsala, Sweden, February 2, 2026.** Dicot Pharma AB has been invited to present the company and its lead candidate drug, LIB-01, at the Oppenheimer 36<sup>th</sup> Annual Healthcare Life Sciences Conference on February 25–26, 2026.

Dicot Pharma has been invited to present the company and its drug candidate LIB-01 at the annual Healthcare Life Sciences Conference organized by the U.S. investment bank Oppenheimer & Co. Inc. The conference highlights a broad range of public and private life science companies and attracts strong institutional interest. Attendance is by invitation only.

Longevity – living a long life in good health – is viewed as a growing trend within the biotechnology industry. In a research report, Oppenheimer highlights that new treatments for erectile dysfunction may play a significant role, and Dicot Pharma's drug candidate LIB#01 is identified as particularly promising for the future.

Dicot Pharma's CEO Elin Trampe will present the company and the drug candidate LIB-01 for the treatment of erectile dysfunction. In October 2025, Dicot Pharma announced positive results from a clinical phase 2a study showing that LIB-01 produced an effect on erectile function that persisted for eight weeks after dosing. The company is also running a preclinical program in metabolic diseases.

**For further information, please contact:**

Elin Trampe, CEO

Phone: +46 72 502 10 10

E-mail: [elin.trampe@dicotpharma.com](mailto:elin.trampe@dicotpharma.com)

**About Dicot Pharma AB**

Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot Pharma's business model involves evaluating industrial and financial partnerships during clinical development to bring LIB-01 to commercialization on the world market.

Dicot Pharma is listed on Nasdaq First North and has approximately 17,300 shareholders. FNCA Sweden AB is appointed Certified Adviser. For more information, please visit [www.dicotpharma.com](http://www.dicotpharma.com).

*This is a translation from the Swedish original. In case of differences between versions, the Swedish version prevails.*